Nordic Society for Pediatric Hematology and Oncology
11
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
45%
5 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Role: collaborator
Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia
Role: collaborator
Thiopurine EnhAnced Maintenance Therapy
Role: collaborator
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Role: lead
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy
Role: collaborator
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase
Role: collaborator
The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia
Role: collaborator
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Role: lead
Second Malignant Neoplasms After Childhood ALL Therapy
Role: collaborator
Registration of Children With CML and Treatment With Imatinib
Role: collaborator
Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses
Role: lead
All 11 trials loaded